Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab...

Area of Science:

• Oncology
• Immunotherapy
• Pathology

Background:

• Brentuximab vedotin (BV) is an antibody-drug conjugate targeting CD30, used for lymphomas like anaplastic large cell lymphoma (ALCL) and classic Hodgkin lymphoma (CHL).
• The impact of BV therapy on CD30 expression levels in patients with ALCL and CHL requires further investigation.

Purpose of the Study:

• To determine the incidence and clinicopathological features of CD30 expression loss or decrease following BV-containing therapy in ALCL and CHL patients.
• To identify potential predictors for CD30 expression changes in response to BV treatment.

Main Methods:

• Retrospective analysis of 12 refractory/relapsed CHL and 9 ALCL patients treated with BV.
• Assessment of CD30 expression via re-biopsy in ALCL patients and comparison with initial biopsy findings.
• Statistical analysis to correlate CD30 expression changes with cumulative BV dose and initial CD30 intensity.

Main Results:

• 44% of ALCL patients (4/9) exhibited CD30 loss or decrease post-BV therapy; none of the CHL patients (0/12) showed this change.
• ALCL patients with CD30 loss/decrease received higher cumulative BV doses (P=0.014) and had lower initial CD30 expression (P=0.017).
• ALCL subtypes (ALK-positive, ALK-negative, primary cutaneous) were not associated with CD30 expression changes.

Conclusions:

• CD30 expression loss/decrease occurs in a significant proportion of ALCL patients treated with BV, irrespective of subtype.
• CHL patients consistently maintain CD30 expression after BV therapy.
• Higher cumulative BV dose and lower baseline CD30 expression may predict CD30 downregulation in ALCL patients receiving BV.